|Bid||5.02 x 1100|
|Ask||5.03 x 1400|
|Day's Range||4.97 - 5.07|
|52 Week Range||4.49 - 8.05|
|Beta (3Y Monthly)||1.76|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 4, 2017 - May 5, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.63|
Anyone researching Cerus Corporation (NASDAQ:CERS) might want to consider the historical volatility of the share...
Cerus Corporation (CERS) announced today a new corporate branding campaign building upon the Company’s leadership position in helping to safeguard the world’s blood supply and the planned relocation of its corporate offices to a new facility in Concord California. The new corporate brand reflects Cerus’ increasingly important role in helping blood centers globally to proactively protect the blood supply against the threat of known and emerging infectious diseases. The Company aims to be the global leader in pathogen reduction technologies and a trusted partner of blood centers and hospitals.
Cerus Corporation (CERS) today announced that the FDA has issued a final guidance document recommending protocols for reducing the risk of transfusion transmitted Babesiosis. In 15 Babesiosis endemic states, treating donated blood components with the INTERCEPT Blood System is a recognized alternative to year-round Babesia testing using a DNA-based test. “We are pleased that treating donated blood components with a pathogen-reduction technology such as INTERCEPT was selected as one of the two options recognized by the FDA to reduce the risk of transfusion transmitted Babesiosis,” said Dr. Richard Benjamin, Cerus’ chief medical officer.
Cerus (CERS) delivered earnings and revenue surprises of -16.67% and 11.42%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Concord, California-based company said it had a loss of 14 cents. The biomedical products company posted revenue of $17.5 million in the period. Cerus expects full-year revenue ...
The fourth quarter was a rough one for most investors, as fears of a rising interest rate environment in the U.S, a trade war with China, and a more or less stagnant Europe, weighed heavily on the minds of investors. Both the S&P 500 and Russell 2000 sank as a result, with the Russell 2000, […]
Cerus (CERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action of the INTERCEPT treatment is designed to inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, as well as emerging pathogens such as chikungunya, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world.
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders have sold shares. So we'll take a look at...
Cerus Corporation (CERS) today announced the closing of a new debt facility with MidCap Financial (MidCap) which is expandable up to $90 million. The debt facility consists of a staged $70 million term loan and a $5 million revolving line of credit, expandable up to $20 million. The new term loan provides an initial tranche of $40 million at closing.
Cerus Corporation (CERS) today announced the appointment of Jami Nachtsheim to its Board of Directors. Ms. Nachtsheim currently serves on the Board at Intuitive Surgical, the global market leader in robotic-assisted minimally invasive surgical systems. Ms. Nachtsheim brings nearly four decades of commercial and marketing leadership experience to the Cerus Board.
Cerus Corporation today announced complete financial results for the fourth quarter and year ended December 31, 2018.
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! The big shareholder groups in Cerus Corporation (NASDAQ:CERS) have powerRead More...
NEW YORK, Feb. 14, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Cerus Corporation announced today that its fourth quarter and full-year 2018 results will be released on Tuesday, February 26, 2019, after the close of the stock market.
In 2011 Obi Greenman was appointed CEO of Cerus Corporation (NASDAQ:CERS). This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. Read More...
Cerus Corporation (CERS) today announced unaudited preliminary product revenue for the fourth quarter and full year 2018 and provided 2019 product revenue guidance. Cerus’ unaudited preliminary product revenue for the fourth quarter of 2018 totaled $16.5 million compared to $16.2 million during the same period the prior year. Based on the fourth quarter unaudited preliminary product revenue, the Company expects full year 2018 product revenue to be $60.9 million, ahead of the top end of the range of the Company’s most recent guidance of $58 million to $60 million.
Mr. Moore joins Cerus from Quest Diagnostics, where he served as Vice President, Lab Operations and was previously the Senior Vice President of Operations, Biomedical Services at the American Red Cross, the world’s largest blood center operation.
Cerus Corporation (CERS) today announced the initiation and first patient enrollment in ReCePI, a randomized, double-blinded, controlled, parallel group, non-inferiority, Phase 3 study to evaluate the efficacy and safety of the INTERCEPT Blood System for red blood cells in patients undergoing complex cardiac surgery procedures. The first patient was enrolled at Houston Methodist Hospital in Houston, Texas. “We are pleased to have started enrollment in ReCePI, our pivotal Phase 3 study,” said Dr. Richard Benjamin, Cerus’ chief medical officer.